Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

GE, Thwaites; M, Scarborough; A, Szubert; E, Nsutebu; R, Tilley; J, Greig; SA, Wyllie; P, Wilson; C, Auckland; J, Cairns; D, Ward; P, Lal; A, Guleri; N, Jenkins; J, Sutton; M, Wiselka; GR, Armando; C, Graham; PR, Chadwick; G, Barlow; NC, Gordon; B, Young; S, Meisner; P, McWhinney; DA, Price; D, Harvey; D, Nayar; D, Jeyaratnam; T, Planche; J, Minton; F, Hudson; S, Hopkins; J, Williams; ME, Török; MJ, Llewelyn; JD, Edgeworth; AS, Walker

doi:10.1016/s0140-6736(17)32456-x

Public

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

Shared by NobleBlocks on Dec 14, 2017 • 12:00 AM UTC

Authors:

Thwaites GE

Scarborough M

Szubert A

Abstract

Background Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!